Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...
with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...
Astellas Pharma Inc. has withdrawn its marketing authorization application from the EMA for its avacincaptad pegol intravitreal solution for the treatment of geographic atrophy secondary to ...
Pharmaceutical Technology on MSN13d
EC approves AstraZeneca’s Fasenra for EGPA treatmentThe European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...
Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or ...
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...
Astellas to withdraw European marketing authorization application for avacincaptad pegol to treat GA secondary to AMD: Tokyo Tuesday, October 29, 2024, 13:00 Hrs [IST] Astellas Ph ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Zacks.com on MSN20d
Novartis Gets CHMP Recommendation for Kisqali in Broader PopulationNovartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...
Moreover, a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) has impacted prospects. They also ...
Astellas has announced the withdrawal of its MAA for ACP from the EMA to treat geographic atrophy (GA) secondary to AMD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback